Hemispherian AS

2:30 PM - 2:45 PM (PDT), Monday, June 13, 2022
Hemispherian is a Norway-based preclinical pharmaceutical company. We are advancing a new class of cancer therapeutics that are specifically designed to treat some of the most aggressive forms of cancer. These drugs are expected to be exceptionally well tolerated resulting in few, if any, side effects. The drugs target the DNA damage response pathway by acting on an entirely new Mechanism of Action that is present uniquely in cancer cells
#glioblastoma #GBM #oncology
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Norway
Year Founded:
2020
Main Therapeutic Focus:
Lead Product in Development:
GLIX1 - Glioblastoma Multiforme
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided